← Back to the library
EducationJanuary 14, 2024 · 4 min read

Breaking the Mold: Discovering Arketamine's Therapeutic Promise

Arketamine is being studied as a possible fast-acting depression treatment. Here’s what the early research suggests—and what it has not shown yet.

Arketamine research, with a molecular model, an unlabelled vial, and a capsule against a blue-violet neural pattern
In this article

Arketamine, also called (R)-ketamine, is one of ketamine’s two mirror-image forms. Researchers are exploring whether it could become another option for people with hard-to-treat depression. The scientific rationale is interesting, but human results so far are mixed—and arketamine is not an approved depression treatment.

What arketamine is

Ketamine is made of two enantiomers, or mirror-image molecules: (R)-ketamine, known as arketamine, and (S)-ketamine, known as esketamine. The two are related, but they are not interchangeable products. The FDA-approved nasal spray Spravato contains esketamine, not arketamine.5

Arketamine has attracted research interest because laboratory and animal studies suggest its effects may differ from those of esketamine. Those findings offer a reason to study it; they do not by themselves tell us whether it will help people with depression.6

What researchers are exploring

Like ketamine and esketamine, arketamine interacts with the brain’s glutamate system, including NMDA receptors. Researchers are studying how that activity may influence communication between brain cells and processes involved in learning and adaptation. The full pathway is still being worked out, so it is more accurate to describe these as research hypotheses than as a settled explanation for an antidepressant effect.6

Animal research has suggested that arketamine might produce longer-lasting antidepressant-like effects and fewer certain behavioral effects than esketamine. That is a promising lead for research, not proof of a similar advantage in people.6

What human studies have found so far

An early open-label pilot followed seven people with treatment-resistant depression after a single arketamine infusion. Symptoms improved on average the next day, an encouraging signal—but because everyone received the treatment and there was no placebo comparison, the study cannot show how much of the change was caused by arketamine.2

A later phase 2a study enrolled 102 people with treatment-resistant depression. Its primary measure—change in depression scores 24 hours after treatment—did not show a statistically significant advantage over placebo. A separate, double-blind pilot with ten participants also did not find a significant difference between arketamine and placebo; its authors noted that the study was very small and affected by a carryover effect.34

A 2025 scoping review found 20 human studies involving 410 people across several uses, including pain and depression. The psychiatric findings were mixed, and many studies were small; the review concluded that larger, well-designed studies are needed before arketamine’s role in care can be established.1

Why the research still matters

Depression can remain difficult to treat, even when someone has tried more than one approach. Studying medicines that act through different brain systems is one way researchers are looking for additional options. Early arketamine studies have raised questions worth answering, including whether particular doses or repeated treatment might help and how benefits and side effects compare with other approaches.12

At the same time, the larger controlled trial’s missed primary endpoint is important. It means the trial did not establish that arketamine worked better than placebo on its main measure. Future research may clarify the picture, but patients and clinicians should not treat a possible future benefit as a current, proven one.3

Safety, dosing, and access

There is no established arketamine dose for treating depression, and it is not FDA-approved for that use. Findings from small studies cannot establish uncommon risks or long-term safety. Arketamine should not be self-administered or purchased as a research chemical; anyone interested in ketamine-related treatment should talk with a qualified clinician about evidence-supported, legally available care.

Esketamine is a separate, FDA-approved treatment for specific adult indications. It has important risks—including sedation, dissociation, respiratory depression, and abuse or misuse—and is given under medical supervision through a restricted program. Those label details apply to esketamine and should not be assumed to define arketamine’s safety profile.5

The bottom line

Arketamine is an active area of scientific interest, and its distinct chemistry gives researchers a thoughtful question to investigate. Early findings are not a treatment promise: controlled human results have been mixed, and arketamine’s benefits, risks, and place in care remain unestablished. If depression is not improving, there are still treatment options worth discussing with a prescriber or mental-health professional; you do not have to wait for an investigational medicine to seek support.134

References

  1. Leal et al. (2025). Arketamine: a scoping review of its use in humans. European Archives of Psychiatry and Clinical Neuroscience.
  2. Leal et al. (2021). Intravenous arketamine for treatment-resistant depression: open-label pilot study.
  3. atai Life Sciences (2023). Phase 2a results for PCN-101 (R-ketamine) in treatment-resistant depression.
  4. Leal et al. (2023). Arketamine as adjunctive therapy for treatment-resistant depression: a placebo-controlled pilot study.
  5. FDA. SPRAVATO (esketamine) prescribing information, revised January 2025.
  6. Zhang, Yao, and Hashimoto (2022). Arketamine, a new rapid-acting antidepressant: a historical review and future directions.
Educational content—not medical advice.Find support resources →